SAN DIEGO — A pneumococcal vaccine elicits effective immunity in patients with end stage liver disease, according to results presented in a poster presentation here at the 55th Annual ICAAC/ICC 2015.
Hsin-Yun Sun, from National Taiwan Univeristy Hospital examined the effects of one dose of the 13-valent pneumococcal conjugated vaccine (Prevnar 13, Pfizer) in 46 patients with liver cirrhosis who were also undergoing liver transplant evaluation, between October 2013 and March 2015.
The researchers measured anticapsular antibody responses against four serotypes – 6B, 14, 19F, and 23F, at baseline and one, three, six, nine months, and a year following vaccination.
The researchers noted that immune responses were generated in between 82 and 95% of the study patients one month after vaccination, and that responses persisted in 73% to 87% of the vaccine recipients at three months and 50 to 80% six months post-vaccination.
- Sun HY. “Patients with end stage liver disease can gain immunity against deadly bacterial infection” Presented at: ICAAC/ICC 2015; Sept. 17-21, 2015; San Diego.